Reversing an earlier rejection, European regulators are recommending early approval for PTC Therapeutics’ ataluren, a treatment for Duchenne muscular dystrophy, news that more than doubled the biotech’s share value in premarket trading.

…read more

Source: PTC soars as EU changes its tune on the DMD-treating ataluren


0 No comments